A Phase I study of the safety, pharmacokinetics and efficacy of navitoclax plus docetaxel in patients with advanced solid tumors.

MLA

Puglisi, Martina, et al. “A Phase I Study of the Safety, Pharmacokinetics and Efficacy of Navitoclax plus Docetaxel in Patients with Advanced Solid Tumors.” Future Oncology (London, England), vol. 17, no. 21, July 2021, pp. 2747–58. EBSCOhost, https://doi.org/10.2217/fon-2021-0140.

APA

Puglisi, M., Molife, L. R., de Jonge, M. J., Khan, K. H., Doorn, L. van, Forster, M. D., Blanco, M., Gutierrez, M., Franklin, C., Busman, T., Yang, J., & Eskens, F. A. (2021). A Phase I study of the safety, pharmacokinetics and efficacy of navitoclax plus docetaxel in patients with advanced solid tumors. Future Oncology (London, England), 17(21), 2747–2758. https://doi.org/10.2217/fon-2021-0140

Chicago

Puglisi, Martina, L Rhoda Molife, Maja Ja de Jonge, Khurum H Khan, Leni van Doorn, Martin D Forster, Montserrat Blanco, et al. 2021. “A Phase I Study of the Safety, Pharmacokinetics and Efficacy of Navitoclax plus Docetaxel in Patients with Advanced Solid Tumors.” Future Oncology (London, England) 17 (21): 2747–58. doi:10.2217/fon-2021-0140.